Neurocrine Biosciences, Inc. <NBIX.O>: RBC cuts target price to $187 from $198
NBIX•Related News
Helus Pharma <HELP.O>: Barclays initiates coverage with Overweight rating; target price $35
HELP•
Global Markets-Stocks rise on AI optimism; lower oil helps bonds
SPY•
Cue Biopharma surges after positive results from mid-stage study for CUE-221
CUE•
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
NVO•
These workers say an AI hiring platform discriminated against them. But who should pay?
WDAY•